Lung Cancer Clinical Trials

Showing 2561-2580 of 4,288 trials

COMPLETED

Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients

NCT04633850

To investigate the effect of intercostal blockade with and without adjuvants.

Postoperative PainLung CancerVideo Assisted Thoracoscopic Surgery+3 more

Jannie Bisgaard Stæhr45 participantsStarted Sep 2020

Aalborg, Region of Northern Jutland, Denmark

UNKNOWN

Neoadjuvant Immune Checkpoint Inhibitor Combined With Chemotherapy in Non-small Cell Lung Cancer

NCT04945200

The primary object of this study is to determine tumor major pathological response (MPR) rate and pathologic complete response (pCR) rate in stage IB-IIIA non-small cell lung cancer who subjected to neoadjuvant immune checkpoint inhibitor combined with chemotherapy and molecular biomarkers related to the clinical response.

Non-small Cell Lung Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University50 participantsStarted Jan 2021

Hangzhou, Zhejiang, China

TERMINATED

Tumor Mutational Burden in Lung Cancer Patients

NCT04289259

Tumor mutational burden (TMB) seems to be is an important marker for immune checkpoint inhibitors efficacy. This study aims to assess the feasibility of the TMB assessment in first-line lung cancer in routine practice both on biopsy and surgical tumor samples. Results will be an element of discussion for the generalization of the TMB implementation in cancer centers.

Non Small Cell Lung CancerNon-Small Cell Carcinoma of LungNon Small Cell Lung Cancer Stage III+1 more

Assistance Publique - Hôpitaux de Paris6 participantsStarted Jun 2020

Clermont-Ferrand, Auvergne-Rhône-Alpes, France • Lyon, Auvergne-Rhône-Alpes, France • Bordeaux, New Aquitaine, France +5 more locations

Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients

Neoadjuvant Immune Checkpoint Inhibitor Combined With Chemotherapy in Non-small Cell Lung Cancer

Tumor Mutational Burden in Lung Cancer Patients

Related Searches

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy

A Multicentre Study of Intraoperative Body Temperature Changes in Patients Undergoing Thoracoscopic Radical Surgery for Lung Cancer

A Micro/Nano Device for Exhaled Breath Analysis

Design and Evaluation of a Novel Methodology for SABR for Lung Cancer

Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.

Osimertinib Study in Indian Patients

Locally Advanced NSCLC Hyperfractionated RT

Lung Cancer Patients' Attitudes to a Second Course of Radiotherapy

Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer

Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy

First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer

Energy for Lymphocytes